Compare DKS & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DKS | INCY |
|---|---|---|
| Founded | 1948 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.0B | 17.0B |
| IPO Year | 2002 | 1994 |
| Metric | DKS | INCY |
|---|---|---|
| Price | $218.22 | $94.89 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 17 | 20 |
| Target Price | ★ $247.00 | $104.05 |
| AVG Volume (30 Days) | 1.0M | ★ 1.2M |
| Earning Date | 05-27-2026 | 04-28-2026 |
| Dividend Yield | ★ 2.30% | N/A |
| EPS Growth | N/A | ★ 4173.33 |
| EPS | ★ 9.97 | 6.41 |
| Revenue | ★ $17,215,120,000.00 | $3,394,635,000.00 |
| Revenue This Year | $30.02 | $10.48 |
| Revenue Next Year | $3.69 | $10.99 |
| P/E Ratio | $21.78 | ★ $15.15 |
| Revenue Growth | ★ 28.06 | 13.67 |
| 52 Week Low | $167.03 | $56.16 |
| 52 Week High | $237.31 | $112.29 |
| Indicator | DKS | INCY |
|---|---|---|
| Relative Strength Index (RSI) | 69.38 | 50.26 |
| Support Level | $214.51 | $93.54 |
| Resistance Level | $218.36 | $108.79 |
| Average True Range (ATR) | 6.58 | 2.50 |
| MACD | 2.77 | 0.58 |
| Stochastic Oscillator | 80.87 | 54.86 |
Dick's Sporting Goods is a retailer that offers sports and outdoor apparel, footwear, and equipment online and in physical stores. The company's legacy business includes more than 700 stores under its own name, more than 110 Golf Galaxy golf specialty stores, and about 50 outlet stores. In September 2025, Dick's acquired multinational retailer Foot Locker. With this move, Dick's added about 2,600 stores under the Foot Locker, Kids Foot Locker, Champs Sports, atmos, and WSS nameplates in North America, the Asia-Pacific, and EMEA—Europe, the Middle East, and Africa. Based in the Pittsburgh area, Dick's was founded in 1948 by the father of current executive chair and controlling shareholder Edward Stack.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.